OS THERAPIES INCORPORATED (OSTX) Debt Components
- 2026-06-30: Short-term DebtUSD (m); Convertible Notes Payable, CurrentUSD (m); Long-Term Debt, Maturity, Year OneUSD $24.00M; Short-term Debt, Weighted Average Interest Rate, at Point in Timepure (m).
- 2026-03-31: Short-term DebtUSD (m); Convertible Notes Payable, CurrentUSD $1.34M; Long-Term Debt, Maturity, Year OneUSD $20.00M; Short-term Debt, Weighted Average Interest Rate, at Point in Timepure (m).
- 2025-12-31: Short-term DebtUSD (m); Convertible Notes Payable, CurrentUSD (m); Long-Term Debt, Maturity, Year OneUSD (m); Short-term Debt, Weighted Average Interest Rate, at Point in Timepure (m).
- 2025-12-31: Short-term DebtUSD (m); Convertible Notes Payable, CurrentUSD (m); Long-Term Debt, Maturity, Year OneUSD $25.00M; Short-term Debt, Weighted Average Interest Rate, at Point in Timepure 8.00%.
OS THERAPIES INCORPORATED Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Short-term Debt USD | Convertible Notes Payable, Current USD | Long-Term Debt, Maturity, Year One USD | Short-term Debt, Weighted Average Interest Rate, at Point in Time pure | Debt Instrument, Convertible, Carrying Amount of Equity Component USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD | Debt Instrument Issued Principal USD | Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed pure |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $24.00M | (m) | $1.35M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $1.34M | $20.00M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $110.00K | (m) |
| 2025-12-31 | (m) | (m) | $25.00M | 8.00% | (m) | $0.00 | (m) | (m) |
| 2025-09-30 | (m) | (m) | (m) | 8.00% | (m) | $0.00 | (m) | (m) |
| 2025-06-30 | (m) | (m) | (m) | 8.00% | (m) | $0.00 | (m) | (m) |
| 2025-03-31 | (m) | (m) | (m) | 8.00% | (m) | $0.00 | (m) | (m) |
| 2024-12-31 | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) |
| 2024-12-31 | (m) | (m) | (m) | 8.00% | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) | 8.00% | (m) | $0.00 | (m) | (m) |
| 2024-06-30 | $250.00K | (m) | (m) | 8.00% | (m) | $0.00 | (m) | (m) |
| 2024-03-31 | $100.00K | $2.28M | (m) | 8.00% | (m) | $0.00 | (m) | (m) |
| 2024-03-07 | $100.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | (m) | $49.84K | (m) | (m) |
| 2023-12-31 | (m) | $2.03M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 5.00% |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |